Safety/tolerability, efficacy and pharmacokinetics of 600-μg cotadutide in Japanese type 2 diabetes patients with a body mass index of 25 kg/m(2) or higher: A phase I, randomized, double-blind, placebo-controlled study

What Was Tested

Researchers studied Cotadutide in this randomized controlled trial publication.

Who Took Part

The abstract describes 2 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

The primary endpoint was safety, including treatment-emergent adverse events (TEAEs); secondary endpoints included glycaemic control and body weight.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Cotadutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Cotadutide.

The comparison arm used a placebo, so changes seen with Cotadutide could be set against what happens without it.

What Was Measured

The subject headings attached to it are Blood Glucose, Blood Glucose Self-Monitoring, Body Mass Index, Diabetes Mellitus, Type 2, East Asian People, Glycated Hemoglobin and Hypoglycemic Agents.

The authors tagged it with the keywords GLP-1, continuous glucose monitoring, glucagon, glycaemic control, phase I study and weight control.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Cotadutide in 2 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Cotadutide compound page, all human trials.